20111 results for «»
20111 results
How should we manage calcific coronary disease according to the European Consensus document?
15 May 2024 – From EuroPCR 2024
Follow this exchange between James Spratt and Flavio Ribichini for insights into how the European Consensus document offers practical guidance for approaching calcified lesions, the significance of angiography findings, the critical role of intravascular imaging (IVUS or OCT), and device selection based on lesion type. Training...
Strengthening cardiovascular care resilience for healthier hearts: the RESIL-Card project
15 May 2024 – From EuroPCR 2024
In this interview at EuroPCR 2024, William Wijns, Niek Klazinga, and Christopher Cook discuss the RESIL-Card initiative, which emerged from the disruption to cardiovascular care during COVID-19. The initiative aims to use this experience to develop a readiness test for future crises. Extensive data has been collected,...
PCR Teaching Assessment Board: innovation in medical education via peer review feedback
15 May 2024 – From EuroPCR 2024
Victoria Jenkins, William Wijns, and Christopher Cook introduce the Teaching Assessment Board, similar to the peer review process in scientific literature. This group provides structured feedback to teachers and participants, inspired by manuscript evaluation methods to enhance educational quality. The aim is to help faculty improve...
Complex PCI in ACS patient with high bleeding risk: optimise the strategy
15 May 2024 – From EuroPCR 2024
Watch this session for insights into managing acute coronary syndrome patients with multivessel disease, updates on treatment approaches, comparing FULL RESVAC with previous trials like COMPLETE or FIRE, for example, and information on ongoing trials such as FRAMI-AMI 2 and 3. Explore the LIVE case presentation...
What is the optimal management of patients with coronary artery disease and left ventricle dysfunction in 2024?
15 May 2024 – From EuroPCR 2024
Check out this EuroPCR 2024 interview between Valeria Paradies and Vasileios Panoulas to learn about CAD patients with LV dysfunction. Gain insights from the REVIVED trial, which shows that very stable, asymptomatic patients can be treated with medical therapy, including the four pillars of heart failure...
Drug-coated balloon PCI for de novo lesions: when and how?
15 May 2024 – From EuroPCR 2024
Michael Haude and Michael Lee discuss various aspects of DCB PCI, emphasizing lesion preparation, dissection management, and the role of imaging and physiology. They touch upon ongoing studies comparing DCB PCI with DES PCI, consider the duration of DAPT in ACS and non-ACS cases, and explore...
Rapid learning curve to TTVR with the Cardiovalve device
15 May 2024 – From EuroPCR 2024
Explore the discussion between Rodrigo Estevez Loureiro and Georg Nickenig on treating tricuspid regurgitation with the innovative Cardiovalve replacement therapy. Learn about the unique features and properties of this low-profile valve with a dual frame, and hear Estevez Loureiro share his firsthand experience using the TTVR...
The LANDMARK trial: early outcomes of a randomised non-inferiority trial comparing TAVI devices
15 May 2024 – From EuroPCR 2024
In this video, Christopher Cook interviews Patrick Serruys about the late-breaking clinical trial data from the LANDMARK RCT. Patrick Serruys begins by explaining the LANDMARK trial, which compares TAVI devices, and emphasizes the complexity of applying VARC-3 criteria. He highlights that the 30-day outcomes confirm the...
First report of an IDE pivotal study of a dedicated splitting device during TAVR
15 May 2024 – From EuroPCR 2024
Watch this interview in which Christopher Cook hosts Martin Leon to discuss pivotal study data on the ShortCut dedicated leaflet splitting device. They revisit the unmet clinical need for leaflet splitting during TAVR: transcatheter valve failures, noting that transcatheter valve failures could surpass surgical bioprosthetic valve failures...
Asymptomatic severe aortic stenosis, how will new evidence change our practice?
15 May 2024 – From EuroPCR 2024
Victoria Delgado and Martin Leon discuss how to treat patients with asymptomatic severe aortic stenosis at an earlier stage and how current trials may change our practice in the future and broaden the indications.
This interview was filmed at EuroPCR 2024: see more videos here.
NOTION-2: first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis
15 May 2024 – From EuroPCR 2024
Christopher Cook interviews Ole de Backer about this study he presented at EuroPCR 2024: It provides further data concerning the 1-year outcome of younger AS patients with tricuspid valve anatomy treated with TAVI compared to SAVR. TAVI and SAVR showed similar rates of the primary endpoint...
Learning from the Masters - Key learnings from 20 years of transcatheter edge-to-edge repair
15 May 2024 – From EuroPCR 2024
Maurizio Taramasso interviews Ottavio Alfieri, a pioneering figure in valve surgery and a key contributor to the development of transcatheter edge-to-edge repair, honored with the Ethica Award at the 2024 edition of #europcr. Ottavio Alfieri discusses his journey to becoming a cardiac surgeon, the genesis of...
LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
15 May 2024 – From EuroPCR 2024
This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography...
What are the key considerations for first-time TAVI in a patient with long life expectancy?
15 May 2024 – From EuroPCR 2024
Interviewed by Dan Blackman, Philip Maccarthy discusses the rising trend of TAVI in younger patients and emphasizes optimizing first-TAVI procedure outcomes for long-term durability. He highlights considerations such as haemodynamics, low gradient, and minimizing paravalvular leak (PVL), as well as the importance of coronary access and...
The future of STEMI care: a new treatment for bridging the gap from diagnosis to treatment
14 May 2024 – From EuroPCR 2024
Watch this session to delve into the crucial role of pre-hospital STEMI diagnosis and treatment. Gain insights into the significance of early intervention and explore previous facilitated PCI trials in STEMI. Additionally, learn about a promising new agent for pre-hospital STEMI treatment, offering potential advancements in...
When and how to treat the side branch in non-left main bifurcations?
16 May 2024 – From EuroPCR 2024
In this video, Jens Flensted Lassen and Thomas Cuisset discuss the importance of the side branch during bifurcation percutaneous coronary intervention (PCI). They emphasize that while there is no perfect solution for all patients, decisions must be tailored to each individual case, often influenced by the patient's...
Interventions for valvular disease: Highlights of EuroPCR 2024
16 May 2024 – From EuroPCR 2024
Christopher Cook hosts Nicolas Dumonteil and Bernard Prendergast as they share EuroPCR 2024 insights on valve disease interventions. Nicolas Dumonteil highlights record-breaking abstracts and cases, demonstrating expertise in TAVI, mitral, and tricuspid procedures. Bernard Prendergast emphasizes LIVE cases, especially in complex TAVI scenarios, reflecting everyday practice. Both stress...
Crossing the finishing line - Latest best practices and technologies for large hole arterial and venous closure
14 May 2024 – From EuroPCR 2024
Tune in to this session for insights on optimizing vascular access and closure techniques. Explore steps like thorough CT analysis, ultrasound-guided puncture, and contingency plans for alternative access methods to minimize complications. Discover a novel patch-based closure approach offering immediate hemostasis and simplified usage, addressing issues...
After ORBITA 2, what is the role of PCI in the contemporary management of patients with angina and coronary disease?
16 May 2024 – From EuroPCR 2024
Emanuele Barbato interviews Rasha Al-Lamee, the principal investigator of the ORBITA 2 trial, about the current role of percutaneous coronary intervention (PCI). Unlike ORBITA 1, ORBITA 2 focused on the effects of angioplasty as a monotherapy, without prior anti-angina treatment. The results showed that angioplasty improved symptoms...
What are the challenges for TAVI in bicuspid disease?
16 May 2024 – From EuroPCR 2024
Raj Makkar and Didier Tchétché address the complexities of bicuspid aortic valve disease, defining ideal candidates for TAVI or replacement and reviewing the NOTION-2 trial, which randomized younger, low-risk patients—including a significant number with bicuspid valves—to TAVI versus surgery. They highlight the importance of embolic protection...
